Loading...
Loading...
INVA| Name | Value |
|---|---|
| Revenues | 91.8M |
| Cost of Revenue | 7.2M |
| Gross Profit | 78.1M |
| Operating Expense | 41.5M |
| Operating I/L | 43.1M |
| Other Income/Expense | -18.4M |
| Interest Income | 5.8M |
| Pretax | 24.7M |
| Income Tax Expense | 4.4M |
| Net Income/Loss | 20.3M |
Innoviva, Inc. specializes in the development and commercialization of pharmaceuticals globally. Their key products include RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA, which are once-daily combination medicines for respiratory conditions. The company has a strategic partnership with Sarissa Capital Management LP and a collaboration agreement with Glaxo Group Limited to develop and market long-acting beta2 agonist (LABA) products for chronic obstructive pulmonary disease and asthma treatment.
